Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

NCT04088890 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

B-ALL
B-cell Non Hodgkin Lymphoma
DLBCL
Follicular Lymphoma Grade 3B

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: CD22 CAR

Sponsor

Matthew Frank

Collaborators

[object Object]
[object Object]
[object Object]